论文部分内容阅读
OBJECTIVE To investigate the value of human epididymis geneproduct 4 (HE4) in differential diagnosis of gynecological pelvictumors.METHODS The level of serum HE4 in 132 women wasdetermined. These women were divided into three groups, i.e.,46 women with good health being classified as the normal control(NC) group, and based on clinicopathological results, the other 86with pelvic masses being classified into groups of benign (n = 56)and malignant lesions (n = 30), respectively.RESULTS The range of serum HE4 in the NC group was(23.5～46.0) pmol/L, with an average value of (34.1 ± 5.6) pmol/L;the range of serum HE4 in the benign lesion group was (30.1～58.9)pmol/L, with an average value of (39.1 ± 7.2) pmol/L; the range ofserum HE4 in the group of malignancy was (31.2～1430.0) pmol/L,and the average value was (248.7 ± 364.5) pmol/L. The level ofHE4 in the malignant lesion group was significantly higher thanthat in the other 2 groups, with a statistical difference, P < 0.001.The diagnostic index reached maximum (0.847) when the serumHE4 was at 51.6 pmol/L, and the sensitivity and specificity of HE4were 86.7% and 98.0%, respectively. The area under the receiver-operator characteristic curve (ROC) was 0.935 (95% CI 0.832～1.037,P = 0.000). The consistency checking Kappa value of HE4 in thediagnosis of pelvic malignant tumors was 0.867, P = 0.000.CONCLUSION The determination of serum HE4 is a goodindicator in differential diagnosis of benign and malignant ovariantumors.
OBJECTIVE To investigate the value of human epididymis gene product 4 (HE4) in differential diagnosis of gynecological pelvictures. METHODS The level of serum HE4 in 132 women wasdetermined. These women were divided into three groups, ie, 46 women with good health being classified as the normal control (NC) group, and based on clinicopathological results, the other 86 with pelvic masses being classified into groups of benign (n = 56) and malignant lesions (n = 30), respectively .RESULTS The range of serum HE4 in the NC group was (23.5 ~ 46.0) pmol / L, with an average value of (34.1 ± 5.6) pmol / L; the range of serum HE4 in the benign lesion was (30.1 ~ 58.9) pmol / L, 39.1 ± 7.2) pmol / L; the range of serum HE4 in the group of malignancy was (31.2-1430.0) pmol / L and the average value was (248.7 ± 364.5) pmol / L. The level of HE4 in the malignant lesion group was significantly higher thanthat in the other 2 groups, with a statistical difference, P <0.001. The diagn The area under the receiver-operator characteristic curve (ROC) was 0.935 (95% CI (87)) when the serum HE4 was at 51.6 pmol / L, and the sensitivity and specificity of HE4were 86.7% and 98.0% 0.832 ~ 1.037, P = 0.000). The consistency checking Kappa value of HE4 in the diagnosis of pelvic malignant tumors was 0.867, P = 0.000.CONCLUSION The determination of serum HE4 is a good indicator in differential diagnosis of benign and malignant ovariant tumors.